MiniMed Group (MMED) just wrapped up FY 2026 with Q4 revenue of US$837 million and a reported loss of US$185 million, translating to basic EPS of a US$0.69 loss for the quarter. Trailing twelve month revenue reached about US$3.1 billion alongside a cumulative loss of US$333 million and EPS of a US$1.30 loss. Over recent periods the company has seen revenue move from US$724 million in Q4 FY 2025 to US$837 million in Q4 FY 2026, while quarterly EPS shifted from a US$0.68 loss to a US$0.69 loss. This sets up a picture of growing sales against earnings that are still under pressure. For investors, the focus is on whether MiniMed Group can translate this higher top line into healthier margins and a clearer path toward sustainable profitability.

See our full analysis for MiniMed Group.

With the headline numbers on the table, the next step is to set these results against the widely followed MiniMed Group narratives to see which stories hold up and which ones look stretched.

14.3% revenue growth but US$333 million annual loss still in focus for MiniMed Group

• Over the last 12 months, MiniMed Group generated about US$3.1 billion in revenue, up from US$2.7 billion a year earlier. This equates to 14.3% reported revenue growth while still posting a cumulative loss of US$333 million.
• What stands out for the bullish view is that solid 14.3% revenue growth and a forecast 63.31% annual earnings improvement sit alongside continuing losses, as trailing EPS moved from a US$0.44 loss two years ago to a US$1.30 loss now. Supporters are therefore leaning on the growth outlook rather than past profitability.
  • Bulls point to the 8.8% forecast annual revenue growth and projected shift to profitability within three years as the bridge from today’s US$333 million loss to a more earnings-driven story.
  • Critics of the bullish angle can point to trailing net income staying in loss territory for multiple years in the data, which means the forecast ramp has not yet shown up in reported profits.

Price-to-sales of 1.4x versus industry 2.7x puts valuation front and center

• MiniMed Group is trading on a P/S of 1.4x compared with 2.7x for the US Medical Equipment industry and 2.0x for peers, while a DCF fair value of US$94.10 sits far above the current US$15.19 share price.
• Supporters with a bullish tilt argue that this discount heavily supports the upside case. Yet the same figures also test how much weight to put on valuation alone when the company is still loss making.
  • The roughly 83.9% gap between the DCF fair value of US$94.10 and the share price of US$15.19 is larger than the 37.7% upside implied by the cited analyst target of US$20.91, which shows analysts are more conservative than the model.
  • Consensus narrative notes that a 1.4x P/S below both industry and peer averages may reflect the current unprofitable status and US$333 million annual loss, so the discount is not cost free in terms of risk.

Investors who want to see how other market participants connect these valuation signals with MiniMed Group's growth and risk profile can tap into the shared narratives in one place using the Curious how numbers become stories that shape markets? Explore Community Narratives.

Cash runway under one year keeps financing risk on the table

• Alongside the loss of US$333 million over the last 12 months and trailing EPS of a US$1.30 loss, MiniMed Group is reported to have less than one year of cash runway, which puts balance sheet capacity in focus while revenue is forecast to grow 8.8% a year.
• Investors leaning toward a more bearish framing highlight that limited liquidity and ongoing losses cut against the upbeat growth narrative, even with strong earnings growth forecasts.
  • Bears argue that with less than one year of cash runway and continuing losses in each trailing period, MiniMed Group may need fresh capital before the forecast earnings improvement arrives.
  • At the same time, the combination of a projected 63.31% annual earnings growth rate and 14.3% reported revenue growth means the bearish concern is not about demand in the last year but about how that growth is funded until profitability is reached.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on MiniMed Group's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Whether you are undecided on MiniMed Group after these results or already leaning bullish or bearish, use the full data set to pressure test your view with the 4 key rewards and 1 important warning sign.

See What Else Is Out There Beyond MiniMed Group

MiniMed Group combines 14.3% revenue growth with a US$333 million annual loss, a cash runway under one year, and no clear track record of sustained profitability so far.

If you are uneasy about that mix of losses and limited liquidity, it makes sense to focus on companies with stronger cushions by starting with the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.